0001209191-23-038844.txt : 20230621 0001209191-23-038844.hdr.sgml : 20230621 20230621172321 ACCESSION NUMBER: 0001209191-23-038844 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230616 FILED AS OF DATE: 20230621 DATE AS OF CHANGE: 20230621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Li Dean Y CENTRAL INDEX KEY: 0001837016 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 231030895 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-16 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001837016 Li Dean Y C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 0 0 0 0 Class A Common Stock 2023-06-16 4 A 0 12612 0.00 A 636021 D Class A Common Stock 1315000 I By Dean Y. Li 2021 GRAT Class A Common Stock 1422048 I By Dean Y. Li Revocable Trust Class A Common Stock 450000 I By Dean Y. Li 2021 Family Trust Stock Option (Right to Buy) 8.92 2023-06-16 4 A 0 25224 0.00 A 2024-06-16 2033-06-16 Class A Common Stock 25224 25224 D Stock Option (Right to Buy) 6.20 2023-06-14 2032-06-14 Class A Common Stock 36290 36290 D Stock Option (Right to Buy) 18.00 2031-04-15 Class A Common Stock 27778 27778 D Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date. /s/ Jonathan Golightly, attorney-in-fact 2023-06-21